Tectonic Therapeutic (TECX) Q3 2024 earnings summary

Executive summary

• Completed a reverse merger with AVROBIO on June 20, 2024, resulting in recapitalization and significant increase in cash resources.

• Lead asset TX45 advanced with positive Phase 1a results, ongoing Phase 1b and Phase 2 trials; topline Phase 1b data expected in late Q1 or early Q2 2025, Phase 2 topline in 2026.

• Patient enrollment in the Phase 1b TX45 trial is ahead of expectations; first subject dosed in APEX Phase 2 trial in October 2024.

• TX2100 selected as a development candidate for HHT, with Phase 1 trial initiation targeted for late 2025 or early 2026.

• No product revenue to date; operations funded by equity, preferred stock, and merger proceeds.

Financial highlights

• Cash and cash equivalents of $159.1 million as of September 30, 2024, down from $185.1 million as of June 30, 2024, and up from $28.8 million at year-end 2023.

• Net loss of $17.7 million for Q3 2024, compared to $10.1 million in Q3 2023; net loss of $45.6 million for the nine months ended September 30, 2024, up from $35.0 million in the prior year period.

• Research and development expenses increased 76% year-over-year to $14.3 million in Q3 2024, driven by TX45 clinical trial progression.

• General and administrative expenses rose 169% year-over-year to $5.3 million in Q3 2024, mainly due to higher stock-based compensation, personnel, consulting, and merger-related costs.

• Total operating expenses for the nine months ended September 30, 2024, were $44.0 million, up 25% from the prior year.

Outlook and guidance

• Cash runway expected to fund operations into mid-2027 based on current plans.

• Topline results for the ongoing Phase 1b TX45 trial expected in late Q1 or early Q2 2025; APEX Phase 2 TX45 trial topline results expected in 2026.

• Phase 1 clinical trial for TX2100 in HHT anticipated to begin in late 2025 or early 2026.

• Anticipates continued increases in R&D and G&A expenses as clinical programs advance and public company costs rise.

• Additional capital will be required for future development and commercialization activities.